NRL972

Phase 2Small molecule

NNorgine

NRL972 is one of 103 small molecule programs targeting Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Non-Alcoholic Fatty Liver DiseaseActive, not recruiting

CirrhosisActive, not recruiting

HepatitisPhase 2

Active, not recruiting

Non-Alcoholic Fatty Liver DiseasePhase 2

Active, not recruiting

CirrhosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Cirrhosis

#DrugCompanyPhaseTrials

Proamatine

Takeda

Preclinical

9 2

NRL972

NNorgine

Phase 2

4 3

Dobutrex

Eli Lilly

Preclinical

1 4

HEPCLUDEX

Gilead

Preclinical

1 5

Farxiga

AstraZeneca

Preclinical

1 6

Revia

Teva

Preclinical

1 7

Cipro

Bayer

Preclinical

1 8

Coreg

Akero Therapeutics

Preclinical

6 9

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

5 10

Cialis

Eli Lilly

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cirrhosis4 trials

Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.

Completed·NNorgine·Phase 3·NCT00794482·1,200 enrolled

Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers

Completed·NNorgine·Phase 1·NCT00856713·72 enrolled

Reproducibility of Child-Turcotte-Pugh (CTP) Rating and NRL972 Pharmacokinetics in Patients With Cirrhosis

Completed·NNorgine·Phase 1·NCT00896597·240 enrolled

Show 1 more trial

Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers

Completed·NNorgine·Phase 1/2·NCT00856869·52 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)

Completed·NNorgine·Phase 2·NCT00794716·125 enrolled

Tics1 trial

Evaluation of the Pharmacokinetics of NRL972 Following Pre-Administration of Rifampicin and Cyclosporine

Completed·NNorgine·Phase 1·NCT00856752·12 enrolled

Hepatitis1 trial

Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.

Completed·NNorgine·Phase 2·NCT00915057·100 enrolled

Unspecified1 trial

Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin

Completed·NNorgine·Phase 1·NCT00857480·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for NRL972. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NRL972 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NRL972. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Norgine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNorgine

NRL972

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cirrhosis4 trials

Non-Alcoholic Fatty Liver Disease1 trial

Tics1 trial

Hepatitis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News